| 1 | Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. (Krook MA, Barker H, Chen HZ, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S) Prostate Cancer Prostatic Dis 2019 Dec;22(4):624-632 7 Citations |
| 1 | Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. (Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM) Int J Radiat Oncol Biol Phys 2019 Aug 01;104(5):1057-1065 13 Citations |
| 2 | Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. (Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM) Lancet Oncol 2018 Nov;19(11):1504-1515 213 Citations |
| 1 | Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM) Cancer 2017 Jul 01;123(13):2489-2496 17 Citations |
| 1 | Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. (Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y) J Allergy Clin Immunol Pract 2015;3(2):206-212.e4 40 Citations |
| 1 | Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. (Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M 3rd, Lawton CA, Sandler HM) Cancer 2015 Mar 15;121(6):844-52 2 Citations |
| 1 | Use of ecallantide in pediatric hereditary angioedema. (MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R) Pediatrics 2013 Aug;132(2):e490-7 31 Citations |
| 1 | Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. (Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE) Allergy Asthma Proc 2013;34(2):155-61 27 Citations |
| 1 | Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. (MacGinnitie AJ, Campion M, Stolz LE, Pullman WE) Allergy Asthma Proc 2012;33(2):178-85 15 Citations |
| 1 | Prologue: kinins and related systems. New life for old discoveries. (Skidgel RA, Alhenc-Gelas F, Campbell WB) Am J Physiol Heart Circ Physiol 2003 Jun;284(6):H1886-91 19 Citations |
| 1 | Alterations in constituent urinary proteins in response to bladder outlet obstruction in rats. (Burns JA, Kreder KJ, Lubaroff DM, See WA) J Urol 1998 May;159(5):1747-51 3 Citations |
| 1 | Urinary excretion of prostaglandin E2, prostaglandin F2 alpha, and thromboxane B2 in normotensive and hypertensive subjects on varying sodium intakes. (Campbell WB, Holland OB, Adams BV, Gomez-Sanchez CE) Hypertension 1982;4(5):735-41 40 Citations |
| 1 | Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency. (Hathaway WE, Wuepper KD, Weston WL, Humbert JR, Rivers RP, Genton E, August CS, Montgomery RR, Mass MF) Am J Med 1976 May 10;60(5):654-64 27 Citations |
